Bio-Rad Laboratories Inc.
BIONYSEFree primer · Steps 1–3 of 21Coverage as of 2026-Q2
TTM ROIC
12.9%FY2023
DCF Fair Value
$417+31%
Moat
Narrow
Op Margin
18.4%FY2023
Net Debt
$420M
Latest Q Revenue
$604M-7% YoYQ3 2024
Top Holder
Schwartz Family35%
Institutional
52.5%
Bull Case
Life Science destocking recovery, Sartorius stake rerating, and operating leverage could unlock substantial upside above consensus.
Bear Case
NIH budget cuts, stalled Life Science recovery, and continued Sartorius deterioration could drive meaningful downside.
Business Model
source: coverage-next-full | ticker: BIO | step: "01" | created: 2026-05-29
Step 01 — Business Overview: Bio-Rad Laboratories Inc. (BIO)
Company Summary
Bio-Rad Laboratories is a global leader in life science research tools and clinical diagnostics, founded in 1952 and headquartered in Hercules, California. The company develops, manufactures, and markets a broad portfolio of products used by researchers, clinicians, and quality control laboratories worldwide. Bio-Rad operates through two segments: Life Science and Clinical Diagnostics, with revenues distributed roughly 40–45% / 55–60% respectively.
Bio-Rad is unique among life science tools companies due to its:
- Schwartz family stewardship — three generations of founding family control via dual-class structure
- Sartorius AG stake — ~12% ownership in Sartorius AG, creating a multi-billion dollar strategic investment
- ddPCR technology leadership — Bio-Rad pioneered and dominates the digital droplet PCR (Droplet Digital PCR, ddPCR) space
Business Segments
Segment 1: Life Science (~40–45% of Revenue)
The Life Science segment serves academic research institutions, pharmaceutical companies, biotechnology companies, government laboratories, and food safety laboratories.
Key Product Lines:
| Product Category | Technology | Use Cases |
|---|---|---|
| Droplet Digital PCR (ddPCR) | QX series instruments + reagent kits | Rare mutation detection, liquid biopsy, gene expression, copy number variation |
| Real-Time PCR (qPCR) | CFX Duet, CFX Opus systems | Gene expression analysis, pathogen detection |
| Gel Electrophoresis / Western Blotting | Trans-Blot Turbo, ChemiDoc systems | Protein analysis, molecular weight determination |
| Cell Imaging & Microscopy | ZOE Fluorescent Cell Imager | Cell biology workflows |
| Protein Interaction / Analysis | GS-900 calibrated densitometer, Bio-Plex multiplex | Protein quantification, cytokine profiling |
| DNA/RNA Purification | Aurum kits | Sample preparation |
| Flow Cytometry | ZE5 Cell Analyzer | Cell sorting, immunophenotyping |
| Chromatography | NGC FPLC systems | Protein purification for bioprocessing/research |
| Food Safety | Genomic-based testing systems | Pathogen detection in food production |
ddPCR Competitive Position:
- Bio-Rad is the originator and dominant player in digital droplet PCR technology
- ddPCR has significant advantages over qPCR for absolute quantification without standards
- Key applications in liquid biopsy (cell-free DNA detection), minimal residual disease (MRD) monitoring, and rare variant detection
- Starplex/Thermo Fisher are attempting competing digital PCR platforms, but Bio-Rad maintains a strong installed base advantage
Life Science Revenue Dynamics:
- Academic/government customers (~40-45% of Life Science revenue) = vulnerable to NIH funding, sequester risk
- Pharma/biotech customers (~50-55%) = high-value, recurring consumables; vulnerable to destocking
- COVID tailwind (2020-2022): ddPCR used extensively for COVID variant detection and diagnostics
- Post-COVID normalization: 2023-2024 saw significant organic revenue decline as biotech/pharma destocked
Segment 2: Clinical Diagnostics (~55–60% of Revenue)
The Clinical Diagnostics segment serves hospital laboratories, blood banks, clinical reference labs, and public health agencies worldwide.
Key Product Lines:
| Product Category | Technology | Use Cases |
|---|---|---|
| Blood Typing / Immunohematology | ID-CARD System (column agglutination) | ABO/Rh typing, antibody screening, crossmatching |
| Serology / Autoimmune | ELISA, multiplex immunoassay | HIV, hepatitis, autoimmune disease testing |
| Quality Controls | Known-value reference materials | Lab QC programs (35,000+ labs globally) |
| Diabetes / Hemoglobin | D-100, D-10 HPLC analyzers | HbA1c testing for diabetes monitoring |
| Specialized Clinical | ELISA, chemiluminescence platforms | Cancer markers, infectious disease |
| Microbiology | Culture and sensitivity testing | Pathogen identification |
Clinical Diagnostics Competitive Position:
- Blood typing: Bio-Rad's ID-CARD (gel-based agglutination) is the #2 global platform behind Ortho Clinical Diagnostics (now QuidelOrtho); strong European position
- Quality controls: Market leader globally — supplies reference materials to 35,000+ clinical labs; high switching costs as labs are accredited around specific QC materials
- Diabetes monitoring: Strong installed base of D-10/D-100 HbA1c analyzers globally
- Clinical Diagnostics is generally more stable than Life Science (hospital budgets vs. research budgets)
Geographic Revenue Mix
| Region | Approximate % of Revenue |
|---|---|
| United States | ~45% |
| Europe | ~35% |
| Asia Pacific & Other | ~20% |
Key geographic observations:
- Strong European presence, particularly in Clinical Diagnostics
- Asia Pacific growing but lower base
- Currency headwinds/tailwinds are meaningful given ~55% international exposure
- China operations subject to geopolitical/procurement risk; has some exposure to Chinese academic and clinical markets
Employees & Operations
- Total employees: ~7,700 globally
- Manufacturing: Multiple facilities in US (Hercules CA, Irvine CA, Redmond WA), Europe (France, Germany), Asia
- R&D headcount: Significant; R&D/Revenue typically 9-12%
- Sales & Marketing: Direct sales force in major markets; distributor network in smaller markets
Sartorius AG Investment
Bio-Rad's ~12% stake in Sartorius AG (Frankfurt: SRT/SRTS) deserves special attention:
- Sartorius AG is a global leader in bioprocess filtration, fermentation, lab instruments (Sartorius Stedim Biotech subsidiary)
- Bio-Rad acquired its stake in 1994 for ~$18M; the investment has compounded massively
- 2021 Peak value: ~$8–9B (when Sartorius AG market cap exceeded €40B)
- 2024 Estimated value: ~$2.5–4B (Sartorius AG declined significantly from bioprocess destocking)
- Bio-Rad marks the stake to fair value each quarter through "Other income (expense)"
- The Sartorius investment provides strategic optionality — could sell to fund acquisitions, buybacks, or special dividends
- Sartorius and Bio-Rad have cross-directorship ties through the Schwartz family
Business Model Summary
Revenue model: ~60%+ of revenues are recurring (reagents, quality controls, consumables tied to installed instrument bases)
Installed base economics:
- Instruments placed at cost or slight loss → decades of reagent revenue
- Switching costs are high once instruments are embedded in lab workflows (software, training, regulatory approval of methods)
- Similar to "razor/blade" dynamic but in professional laboratory context
Margin profile:
- Gross margins: ~55–57% consolidated
- Operating margins: historically 8–14% (compressed by R&D investment and period costs)
- Life Science margins: somewhat higher than Clinical Diagnostics
- Margin compression during 2023-2024 from revenue decline vs. semi-fixed cost base
Key Investment Themes
- Sum-of-parts opportunity: Sartorius stake + operating business potentially worth more separately than current market cap implies
- Destocking recovery: Life Science organic growth should normalize/accelerate in 2025-2026 as biotech/pharma restocks
- ddPCR platform: Leading position in a growing technology with expanding applications (liquid biopsy, oncology, gene therapy QC)
- Margin recovery: As revenues recover, operating leverage should drive meaningful margin expansion
- Family stewardship: Conservative capital allocation, no short-termism, willing to hold Sartorius stake long-term
- Clinical Diagnostics stability: Blood typing / quality controls provide durable recurring revenue floor
Financial Snapshot
source: coverage-next-full | ticker: BIO | step: "04" | created: 2026-05-29
Step 04 — Financial Snapshot: Bio-Rad Laboratories Inc. (BIO)
GAAP P&L Summary (FY2021–FY2024E)
All figures in USD millions except per-share
| Metric | FY2021 | FY2022 | FY2023 | FY2024E |
|---|---|---|---|---|
| Revenue | $3,025 | $2,802 | $2,580 | ~$2,380 |
| Life Science | $1,358 | $1,281 | $1,081 | ~$960 |
| Clinical Diagnostics | $1,667 | $1,521 | $1,499 | ~$1,420 |
| Gross Profit | ~$1,682 | ~$1,539 | ~$1,392 | ~$1,270 |
| Gross Margin | 55.6% | 54.9% | 54.0% | ~53.5% |
| R&D Expense | ~$304 | ~$274 | ~$253 | ~$225 |
| R&D / Revenue | 10.0% | 9.8% | 9.8% | ~9.5% |
| SG&A Expense | ~$804 | ~$719 | ~$666 | ~$610 |
| Operating Income | ~$575 | ~$546 | ~$474 | ~$435 |
| Operating Margin | 19.0% | 19.5% | 18.4% | ~18.3% |
| Adjusted Operating Margin | ~14–17% | ~13–15% | ~10–12% | ~9–11% |
| Interest Income (Expense), net | ~$15 | ~$35 | ~$55 | ~$65 |
| Other income (expense) — Sartorius MTM | +$4,211 | -$4,543 | -$2,100 | ~-$500 to +$500 |
| Pre-tax Income | ~$4,802 | -$3,963 | -$1,571 | ~varies |
| Net Income (GAAP) | ~$3,745 | -$3,246 | -$1,401 | ~varies |
| Diluted EPS (GAAP) | ~$124 | -$108 | -$47 | ~varies |
| Adj. EPS (ex-Sartorius MTM) | ~$15–20 | ~$12–18 | ~$8–12 | ~$7–12 |
Critical Note on Sartorius Mark-to-Market:
- Bio-Rad holds ~37.8M Sartorius AG ordinary shares, accounted for at fair value through P&L
- FY2021: Sartorius AG stock surged ~200%+ → ~$4.2B unrealized gain
- FY2022: Sartorius AG fell ~60%+ → ~$4.5B unrealized loss
- FY2023: Sartorius continued declining → ~$2.1B additional unrealized loss
- These swings make GAAP EPS effectively meaningless for fundamental analysis
- Analysts and investors universally focus on Adjusted EPS (ex-Sartorius MTM)
Segment Financial Performance
Life Science Segment
| Metric | FY2021 | FY2022 | FY2023 | FY2024E |
|---|---|---|---|---|
| Revenue | $1,358M | $1,281M | $1,081M | ~$960M |
| YoY Growth | +18.4% | -5.7% | -15.6% | ~-11% |
| Organic Growth | +15–17% | +4–7% | ~-16% | ~-9 to -12% |
| Segment Op. Income | ~$215M | ~$185M | ~$115M | ~$85M |
| Segment Op. Margin | ~15.8% | ~14.4% | ~10.6% | ~8.8% |
Clinical Diagnostics Segment
| Metric | FY2021 | FY2022 | FY2023 | FY2024E |
|---|---|---|---|---|
| Revenue | $1,667M | $1,521M | $1,499M | ~$1,420M |
| YoY Growth | +8.3% | -8.8% | -1.4% | ~-5% |
| Organic Growth | +5–8% | +0–3% | ~0–2% | ~0–2% |
| Segment Op. Income | ~$360M | ~$361M | ~$358M | ~$350M |
| Segment Op. Margin | ~21.6% | ~23.7% | ~23.9% | ~24.6% |
Note: Segment operating income includes segment-allocated overhead; corporate unallocated costs excluded from segment margins
Key Financial Metrics Timeline
Revenue & Profitability
| Period | Revenue | Op. Margin | Adj. EPS | FCF Margin |
|---|---|---|---|---|
| FY2019 | $2,313M | ~12.5% | ~$8–10 | ~7–9% |
| FY2020 | $2,779M | ~16.5% | ~$12–15 | ~10–12% |
| FY2021 | $3,025M | ~19.0% | ~$15–20 | ~12–14% |
| FY2022 | $2,802M | ~19.5% | ~$12–18 | ~10–12% |
| FY2023 | $2,580M | ~18.4% | ~$8–12 | ~7–10% |
| FY2024E | ~$2,380M | ~18.3% | ~$7–12 | ~6–9% |
Adj. EPS excludes Sartorius MTM, acquisition-related amortization, restructuring charges
Revenue Decline Trajectory
FY2021 Peak: $3,025M
↓ -7.4%
FY2022: $2,802M
↓ -7.9%
FY2023: $2,580M
↓ ~-8%
FY2024E: ~$2,380M
Total revenue decline from FY2021 peak to FY2024E trough: ~-21% Revenue recovery scenario to FY2021 peak: Would require ~+27% growth; likely 4–6 years at normalized growth
Balance Sheet Snapshot
As of most recent reporting (FY2023/Q3 2024 approximate)
| Metric | Value |
|---|---|
| Cash & Equivalents | ~$620–650M |
| Sartorius Stake (Fair Value) | ~$2,500–4,000M (market-dependent) |
| Total Assets | ~$6,500–8,500M (Sartorius-dependent) |
| Total Debt (Long-term) | ~$1,050–1,100M |
| Net Debt (ex-Sartorius) | ~$420–480M |
| Net Debt (inc. Sartorius at FV) | Net cash position by significant margin |
| Total Equity (GAAP) | ~$3,500–5,500M (Sartorius-dependent) |
| Book Value / Share | ~$115–185 (heavily Sartorius-influenced) |
Balance Sheet Interpretation:
- Excluding Sartorius, Bio-Rad has modest net debt (~$400–500M) relative to EBITDA
- Including the Sartorius stake, the company has significant net asset value
- Leverage is manageable; interest coverage remains comfortable even in trough conditions
Per-Share Metrics
| Metric | FY2021 | FY2022 | FY2023 | FY2024E |
|---|---|---|---|---|
| Diluted shares outstanding | ~30.2M | ~30.1M | ~29.9M | ~29.8M |
| GAAP EPS | +$124 | -$108 | -$47 | N/A |
| Adj. EPS (ex-MTM) | ~$17 | ~$14 | ~$10 | ~$8–12 |
| FCF per share | ~$12–16 | ~$10–14 | ~$7–10 | ~$6–9 |
| Book value per share | ~$150+ | ~$55 | ~$65 | ~$85–100 |
Book value per share heavily influenced by Sartorius MTM fair value changes
Important Accounting Notes
1. Sartorius Mark-to-Market Treatment
- Bio-Rad adopted ASU 2016-01 (fair value through P&L for equity investments)
- Sartorius AG ordinary shares marked to market every quarter
- Unrealized gains/losses flow through the "Other income (expense)" line in the income statement
- This is a non-cash item — but it impacts GAAP EPS dramatically
- For analysis purposes, always use Adjusted EPS or Operating Income (ex-Sartorius)
2. Restructuring Charges
- Bio-Rad announced restructuring programs in 2023–2024 targeting ~$60–100M annualized savings
- Restructuring charges (~$50–150M over 2023–2025) are one-time costs but occur regularly
- Targeted headcount reduction and real estate footprint rationalization
3. Amortization of Acquired Intangibles
- Historical acquisitions (RainDance Technologies, etc.) generate amortization
- ~$50–80M annual intangible amortization runs through COGS and operating expenses
- Adjusted metrics typically add back acquisition-related amortization
4. Revenue Recognition
- ASC 606 compliant; instruments recognized at point of delivery
- Reagent/consumable revenue recognized at shipment/delivery
- Service contract revenue recognized ratably over contract term
- No significant multiple-element arrangement complexity
Key Financial Ratios (FY2023, Approximate)
| Ratio | Value | Context |
|---|---|---|
| P/E (GAAP) | N/M (loss year) | Not meaningful due to Sartorius MTM |
| P/E (Adjusted) | ~35–45x | Premium multiple for life science tools |
| EV/EBITDA | ~20–30x | Varies significantly with Sartorius stake backing |
| EV/Revenue | ~3.0–4.5x | Life science tools sector typical |
| Price/Book | ~2–3x | Distorted by Sartorius MTM |
| Gross Margin | 54.0% | Solid for diversified instruments/diagnostics |
| Adj. Operating Margin | ~10–12% | Depressed from FY2021 peak of ~17% |
| Net Debt / EBITDA | ~1.0–1.5x | Ex-Sartorius; manageable |
| FCF Conversion | ~60–75% of net income | Solid capital discipline |
Recent Catalysts
source: coverage-next-full | ticker: BIO | step: "12" | created: 2026-05-29
Step 12 — Catalysts: Bio-Rad Laboratories Inc. (BIO)
Catalyst Framework
Bio-Rad's stock performance is driven by three primary catalyst categories:
- Life Science recovery pace — The most debated near-term driver
- Sartorius stake value — Creates GAAP earnings volatility and sum-of-parts debate
- Margin expansion — Operating leverage story as revenues recover
Near-Term Catalysts (6–12 Months)
Catalyst N1: Life Science Organic Growth Turns Positive
- What: First quarter of positive Life Science organic revenue growth (vs. -10–18% trough)
- When: Most analyst consensus expects Q1–Q2 2025
- Signal importance: Pivotal; market is waiting for evidence that destocking is over
- Price impact: Positive surprise → significant re-rating; likely +10–20% stock upside
- Risk: If recovery delayed to H2 2025 or later → negative re-rating
Catalyst N2: Q4 2024 / FY2025 Guidance
- What: Management's FY2025 revenue and margin guidance at Q4 2024 earnings (~Feb 2025)
- When: February 2025 (estimated)
- Market expectation: ~3–7% organic growth in FY2025; adj. operating margin improvement to 12–14%
- Price impact: Above-consensus guidance = 10–15% upside; below = 10–15% downside
- Key metric to watch: Life Science guidance; Clinical Diagnostics is less contested
Catalyst N3: Restructuring Savings Flowing Through
- What: Full recognition of $60–100M annualized restructuring savings in P&L
- When: FY2025 (primary year of benefit recognition)
- Margin impact: ~250–400 bps adj. operating margin improvement
- Stock impact: Confirms operating leverage thesis; moderate positive
Catalyst N4: Sartorius AG Recovery
- What: Sartorius AG organic growth turning positive; margin recovery; share price re-rating
- When: H2 2024 – H1 2025 (Sartorius recovery expected in 2025)
- Bio-Rad impact: Every €100 increase in Sartorius AG share price = ~$800M increase in Bio-Rad's Sartorius stake value
- GAAP impact: Large positive "Other income" flowing through P&L
- Sum-of-parts impact: Increases Sartorius contribution to Bio-Rad fair value
- Caution: Market may not re-rate Bio-Rad purely on GAAP earnings improvement; focus remains on operating business
Medium-Term Catalysts (1–3 Years)
Catalyst M1: ddPCR Adoption in Liquid Biopsy and Oncology
- What: Broader FDA clearance and clinical adoption of ddPCR for MRD (minimal residual disease) monitoring in cancer
- Timeline: 2025–2027
- Market size: Liquid biopsy TAM $3–8B by 2030; ddPCR could capture $500M–1B
- Stock impact: Significant if Bio-Rad establishes a dominant clinical ddPCR position
- Risk: Illumina/Foundation Medicine / Guardant Health use NGS platforms; ddPCR competes in specific niches only
Catalyst M2: Gene Therapy QC Market Maturation
- What: Gene therapy market expanding → ddPCR demand for viral vector characterization (AAV, lentiviral)
- Timeline: 2025–2030
- Bio-Rad position: ddPCR is the preferred method for viral genome titer quantification (regulatory standard)
- Market impact: Every $1B in gene therapy product revenue generates ~$15–25M in ddPCR consumable demand
- Stock impact: Structural demand driver; modestly positive incremental revenue
Catalyst M3: Sartorius Partial Monetization / Capital Return
- What: Bio-Rad sells 5–15% of Sartorius stake and deploys proceeds for buyback or special dividend
- Timeline: 1–3 years (possible but not certain)
- Stake value at 15% trim: ~$420–480M proceeds (at base case Sartorius price) → ~$350–380M net of taxes
- Per-share impact: Could fund buyback of ~1.2–1.5M shares (4–5% of float) → meaningful accretive
- Stock re-rating: Sum-of-parts discount could narrow by 10–15% upon partial monetization
- Probability: ~20–30% over next 2 years
Catalyst M4: Operating Margin Recovery to 14–16%
- What: As revenues recover toward $2.8–3.0B, operating leverage drives margin recovery
- Timeline: FY2026–2027
- Margin trajectory: 9–10% (2024) → 12–14% (2025) → 14–16% (2026–2027)
- EPS impact: At $3.0B revenue and 15% op. margin = ~$450M op. income → ~$350M net income → ~$11–13 adj. EPS
- Valuation impact: At 30x adj. P/E = $330–390 stock price; meaningful upside vs. current ~$280–320
Long-Term Catalysts (3–5+ Years)
Catalyst L1: Sum-of-Parts Recognition
- What: Market gives Bio-Rad full credit for Sartorius stake + operating business value
- Scenario: Sartorius stake at $3B net of tax ($100/share) + operating business at 20x EV/EBITDA = $200–250/share → total fair value $300–350+
- Current discount: Market appears to apply ~20–30% holding company discount to Sartorius stake
- Catalyst: Activist investor pressure, partial sale, or simply Sartorius recovery narrowing the gap
Catalyst L2: M&A Takeout / Strategic Combination
- What: Larger life science company (Thermo, Danaher, Abbott) acquires Bio-Rad or its operating assets
- Probability: Low — Schwartz family dual-class control makes hostile takeover impossible; family unlikely to sell
- Premium if it happened: 30–50% premium to current price
- Optionality value: Provides a floor on valuation for sum-of-parts investors
Reverse Catalysts (Downside)
Reverse Catalyst R1: Life Science Recovery Stalls
- Organic growth remains negative through FY2025
- Drivers: NIH budget cuts, prolonged biotech funding weakness, China market deterioration
- Downside impact: -20–30% from current price
Reverse Catalyst R2: Sartorius AG Continues Declining
- Sartorius AG business fundamentals deteriorate further; share price falls to €100–120
- Bio-Rad stake value: ~$1.5–1.8B (vs. ~$2.8–3.2B today)
- GAAP impact: Additional multi-billion dollar reported losses
- Sum-of-parts impact: Reduces Bio-Rad fair value by ~$35–50/share
Reverse Catalyst R3: NIH Budget Cuts Materialize
- DOGE-related NIH budget cuts of 20–30% flow through to academic lab spending in FY2025–2026
- Life Science recovery pushed back; margins compressed longer
- Revenue impact: -$80–150M incremental headwind
Bull Case
- Life Science organic growth returns to 5–8% by mid-2025, confirming destocking is complete and driving significant earnings upgrade cycle with operating leverage
- Sartorius AG shares recover 50–70% as bioprocess market normalizes, adding $1–1.5B in stake value and triggering sum-of-parts re-rating of Bio-Rad
- Bio-Rad monetizes 10% of Sartorius stake at recovered prices, funding a $300–400M buyback that reduces shares outstanding by 4–5% and narrows the holding company discount
Bear Case
- NIH budget cuts of 20–25% extend Life Science revenue declines through FY2025, pushing adj. operating margin below 8% and triggering further consensus earnings cuts
- Sartorius AG recovery disappoints and shares decline to €100–120, reducing Bio-Rad's stake value to ~$1.5–1.8B and creating another year of multi-billion dollar GAAP losses that drive retail investor selling
- ddPCR competitive pressure intensifies as key patents expire 2025–2027, with Thermo Fisher aggressively pricing competing digital PCR systems to displace Bio-Rad in new lab placements
Full Research Available
This primer covers steps 1–3 of 21. The full deep dive includes moat analysis, DCF valuation, bull/bear scenarios, management quality, earnings transcript analysis, competitive positioning, returns on capital, institutional/insider activity, and an investment memo.
View Investment MemoEach memo is $2. Coverage subscriptions for funds coming soon — join the waitlist.